Compare GRPN & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | BLFS |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.9M | 1.3B |
| IPO Year | 2011 | 1989 |
| Metric | GRPN | BLFS |
|---|---|---|
| Price | $17.83 | $25.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $31.25 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 1.2M | 375.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $496,093,000.00 | $100,144,000.00 |
| Revenue This Year | $4.17 | $20.67 |
| Revenue Next Year | $10.63 | $14.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $9.21 | $19.10 |
| 52 Week High | $43.08 | $29.62 |
| Indicator | GRPN | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 45.31 |
| Support Level | $16.47 | $24.68 |
| Resistance Level | $17.08 | $27.24 |
| Average True Range (ATR) | 0.92 | 1.02 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 70.34 | 49.32 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.